biomaterial

(redirected from Biomaterials)
Also found in: Medical, Encyclopedia.

bi·o·ma·te·ri·al

 (bī′ō-mə-tîr′ē-əl)
n.
A biocompatible material that is used to construct artificial organs, rehabilitation devices, or prostheses and replace natural body tissues.

[bio(compatible) + material.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

biomaterial

(ˌbaɪəʊməˈtɪərɪəl)
n
a synthetic material used in prostheses or the replacement of natural body tissues
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

bi•o•ma•te•ri•al

(ˌbaɪ oʊ məˈtɪər i əl, ˈbaɪ oʊ məˌtɪər-)

n.
a natural or synthetic material that is compatible with living tissue and is suitable for surgical implanting.
[1965–70]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
Translations
References in periodicals archive ?
M2 PRESSWIRE-August 1, 2019-: Nerve Repair Biomaterials Market In 2019 | Prominent Players: Stryker, axogen, Checkpoint Surgical, Medtronic, Boston Scientific, Polyganics BV, Abbott, LivaNova, Nuvectra, Baxter
Patent application for new technology enabling low-cost production of PHA-based biomaterials in Camelina sativa, an oilseed crop.
The 18 papers in the collection report the findings of research on biomaterials for the medical and energy fields and biopolymers for the fabrication of biomaterials.
Tn today's environment, biomaterials must be effective as customers are striving to reduce OR time and get patients ambulatory and out of care facilities sooner.
M2 EQUITYBITES-September 5, 2018-AdvanSource Biomaterials reports extension of license and royalty agreement with Access Scientific
Global Banking News-September 5, 2018-AdvanSource Biomaterials reports extension of license and royalty agreement with Access Scientific
M2 PHARMA-September 5, 2018-AdvanSource Biomaterials reports extension of license and royalty agreement with Access Scientific
in Biomaterials in 2007 and a Master's Degree in Medical Science in 2003 from Tokyo Medical and Dental University.
Active research in this area started way back in 1970 when the term 'biomaterials' was coined to represent the class of materials having potential use in medicine, other than drugs.
Biomaterials offer an alternative approach that may overcome these limitations.
The team subsequently plans to investigate how hydrogel-based biomaterials can be injected into severely damaged brain regions to improve brain tissue regeneration.